+ 34 986 812 316

Southampton Cancer Research Centre. Molecular Oncology
University of Southampton, Cancer Sciences Unit, Somers Cancer Research Building, Mail Point 824, Southampton General Hospital, Tremona Road, Southampton SO16 6YD
United Kingdom

lymphoma, leukaemia, antigen receptor, signalling, gene expression, EZH2, LSD1, KDM5


Primary human lymphoma and leukaemia cells; in vitro studies including microenvironmental stimulational; mouse models


Primary cancer cells, multicolour flow cytometry, immunoblotting, gene expression, ribosome profiling, signal analysis, normal B cell isolation, mRNA translation - single cell analysis

Collaborations outside COST

Short description of ongoing research projects

Graham Packham has a first class honours degree in Biochemistry from the University of Leeds. He was awarded his PhD in 1992 from the University of London, following studies on regulation of Epstein-Barr virus gene expression at the Ludwig Institute for Cancer Research at St Mary’s Hospital, London. Professor Packham carried out his postdoctoral research at St Jude Children’s Research Hospital in Memphis, USA, where he was the recipient of the Martin Morrison Fellowship, investigating mechanisms of action of the c-Myc oncoprotein in the laboratory of Dr John Cleveland. He returned to the Ludwig Institute for Cancer Research in 1995 to establish an independent research group studying the molecular regulation of apoptosis in cancer cells. Professor Packham joined the Cancer Sciences Division of the University of Southampton as a Senior Lecturer in 2000 and was appointed Professor of Molecular Oncology in 2006. Professor Packham leads a research group investigating molecular mechanisms controlling proliferation and survival in malignant lymphocytes and developing novel chemical compounds to interfere with key cancer promoting pathways. He has published more than 130 peer-reviewed papers and patents. Graham Packham is also a cofounder of Karus Therapeutics, a University spin-out company involved in the development of novel therapeutics for cancer and inflammatory disease. Our main interest is in the biology of human leukaemia and lymphoma, with a focus on primary patient derived material to avoid potential artefacts associated with established cell lines. For epigenetics, current targets include EZH2, KMD5 and BRD. We also have associated programmes investigated epigenetic regulation of the androgen receptor in prostate cancer (with Dr Simon Crabb) and miRNAs (and other nc-RNAs) in colon cancer (with Drs Alex Mirnezami and Marc Bullock).

  1. Yeomans A, Thirdborough SM, Valle-Argos B, Linley A, Krysov S, Sanchez Hidalgo M, Leonard E, Ishfaq M, Wagner SD, Willis AE, Steele AJ, Stevenson FK, Forconi F, Coldwell MJ, Packham G. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. Blood. 2015 Oct 21.
  2. Linley A, Krysov S, Ponzoni M, Johnson PW, Packham G, Stevenson FK. Lectin binding to surface Ig variable regions provides a universal persistent activating ignal for follicular lymphoma cells. Blood. 2015 Oct 15;126(16):1902-10
  3. Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock MD, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida I, Hsiao A, Zhang X, Primrose JN, Packham GK, Liu K, Bojja K, Gafà R, Xiao L, ossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, onescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, irnezami AH, Calin GA, Nicoloso MS. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut. 2015 Mar 24. pii: utjnl-2015-309372. doi: 10.1136/gutjnl-2015-309372.
  4. Okosun J, Packham G, Fitzgibbon J. Investigational epigenetically targeted rugs in early phase trials for the treatment of haematological malignancies. xpert Opin Investig Drugs. 2014 Oct;23(10):1321-32.
  5. Tortorici M, Borrello MT, Tardugno M, Chiarelli LR, Pilotto S, Ciossani G, Vellore NA, Bailey SG, Cowan J, O'Connell M, Crabb SJ, Packham G, Mai A, Baron R, Ganesan A, Mattevi A. Protein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylase. ACS Chem Biol. 2013 Aug 16;8(8):1677-82
Other activities of potential interest to others

Cost UE